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Background: Non-invasive imaging of inflammation to measure the progression of autoimmune diseases, such as
rheumatoid arthritis (RA), and to monitor responses to therapy is critically needed. V-Sense, a perfluorocarbon (PFC)
contrast agent that preferentially labels inflammatory cells, which are then recruited out of systemic circulation to
sites of inflammation, enables detection by 19F MRI. With no 19F background in the host, detection is highly-specific
and can act as a proxy biomarker of the degree of inflammation present.
Methods: Collagen-induced arthritis in rats, a model with many similarities to human RA, was used to study the
ability of the PFC contrast agent to reveal the accumulation of inflammation over time using 19F MRI. Disease
progression in the rat hind limbs was monitored by caliper measurements and 19F MRI on days 15, 22 and 29,
including the height of clinically symptomatic disease. Naïve rats served as controls. The capacity of the PFC
contrast agent and 19F MRI to assess the effectiveness of therapy was studied in a cohort of rats administered oral
prednisolone on days 14 to 28.
Results: Quantification of 19F signal measured by MRI in affected limbs was linearly correlated with disease severity.
In animals with progressive disease, increases in 19F signal reflected the ongoing recruitment of inflammatory cells
to the site, while no increase in 19F signal was observed in animals receiving treatment which resulted in clinical
resolution of disease.
Conclusion: These results indicate that 19F MRI may be used to quantitatively and qualitatively evaluate
longitudinal responses to a therapeutic regimen, while additionally revealing the recruitment of monocytic cells
involved in the inflammatory process to the anatomical site. This study may support the use of 19F MRI to clinically
quantify and monitor the severity of inflammation, and to assess the effectiveness of treatments in RA and other
diseases with an inflammatory component.
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Rheumatoid arthritis is a systematic, chronic, debilitating
disease which affects approximately 0.5-1% of the world
population [1,2]. Inflammation of the synovial membrane
is a hallmark of the disease, with the disease eventually
progressing to cartilage and osseous degradation. There is
no known cure, however therapeutic treatments are* Correspondence: awesa@celsense.com
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reproduction in any medium, provided the oravailable and recent advances in the imaging of the disease
and associated inflammation have allowed earlier diagno-
sis and intervention [3,4], with the possibility for increased
mobility and quality of life for patients through disease
management [5-7].
Imaging for arthritis, or inflammation in general, can be
classified as either anatomical imaging, where the manifes-
tations of the disease on the body are observed, or biofunc-
tional imaging, where the biological processes involved in
the disease are observed [8]. In the case of RA, imaging for
clinical diagnosis is limited to anatomical imaging of bonel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(ultrasound, MRI), and joint effusion and tissue swelling
(x-ray) [9,10]. These techniques, though useful, often only
elucidate the disease after permanent damage is done, limit-
ing the applicability of early intervention therapies [11].
Biofunctional imaging of arthritis focuses on metabolic ac-
tivity, cellular infiltrates, and cytokine production [10],
which often occur prior to the onset of permanent anatom-
ical damage due to the disease. It may serve as an indicator
of the presence of disease and severity, enabling earlier
diagnosis and treatment [3]. By example, in RA patients
with clinically stable disease, synovitis may persist, leading
to disease progression [12]. Methodologies for non-invasive
detection and localization of inflammation in RA include
PET/CT [13], ultrasound [14], optical (fluorescence) im-
aging [15], and MRI.
MRI is of particular interest due to its high spatial reso-
lution, which allows precise anatomical visualization of
bone degradation, and its current role in the diagnosis of
RA [16]. Furthermore, the safety profile of MRI makes it
amenable to repetitive imaging sessions, an important con-
sideration for use in a prolonged, chronic disorder. MRI
images of macrophage infiltration associated with inflam-
mation have been obtained in a variety of disease states
using transition metal and super paramagnetic iron oxide
(SPIO) contrast agents [17]. Gadolinium has been used as a
blood-pool marker of sites of inflammation [18,19] and
quantitative methods using the reagent have been devel-
oped [20-22]. SPIO nanoparticles are phagocytosed by cir-
culating monocytes/macrophage, and provide MR contrast
when those cells aggregate at the site of inflammation
[23-27]. Unfortunately, metal-based MR contrast agents op-
erate by either increasing or decreasing the signal obtained
in the MRI image, effectively convoluting the anatomical
image with cell-level information and impeding normal ob-
servation of disease progression with the technique. The
use of an alternate nucleus, such as fluorine MRI (19F MRI)
avoids this difficulty by specific detection of the fluorine
atom, providing a signal which varies in a direct relation-
ship with the amount 19F present, without any background
signal from host tissue, and without distorting the anatom-
ical 1H image.
19F MRI with the use of a perfluorocarbon (PFC) con-
trast agent has emerged as a powerful technique through
the in situ labeling of circulating macrophage and mono-
cytes. Labeled inflammatory cells traffic to sites of inflam-
mation where they accumulate and render those tissues
detectable by 19F MRI. This approach has been used as an
indicator of inflammation in a variety of disease models
including experimental autoimmune encephalitis [28],
allograft rejection [29,30], inflammatory bowel disease
[31], abscess visualization [32], pulmonary inflammation
[33], and post-ischemia inflammation in the heart and
brain [34]. Un-inflamed tissues (with the exception of thereticuloendothelial system) lack 19F signal, and therapeutic
intervention can modulate the 19F intensity [31,33], indi-
cating the specificity of this approach for inflamed tissues.
Furthermore, the 19F signal correlates with the degree of
macrophages present in the inflammatory site [28]. How-
ever, no correlation to disease severity has yet been estab-
lished through co-measurement of 19F MRI and with a
clinical marker.
Here, we employ a well-known model of RA, with a fa-
cile, independent measurement of clinical disease progres-
sion (ankle diameter), to validate the ability of 19F MRI to
ascertain disease presence and severity. The current study
has two aims: (1) to evaluate the ability of 19F MRI to quan-
titatively measure disease severity relative to standard mea-
surements, and (2) to determine whether serial imaging
with 19F MRI reflects the course of disease progression or
response to therapy.
Methods
Animals, arthritis model and treatment
All animal studies were conducted with Institutional
IACUC approval at a contract research organization
(Covance Laboratories, Greenfield, IN). Female Lewis rats
were purchased from Charles River, and housed under spe-
cific pathogen-free (SPF) conditions. The rat collagen
induced arthritis (CIA) model was conducted as previously
described [35,36]. Briefly, Lewis rats received two weekly
doses of Type II bovine collagen (CII, 2 mg/mL) in incom-
plete Freund’s adjuvant, intradermally, leading to the onset
of arthritis with clinical symptoms appearing by day 14 after
the initial immunization, peak swelling in the limb joints by
day 21 and arthritic damage by day 28. Naïve animals
served as controls, and were housed until day 28. The de-
velopment of arthritis and severity was measured by paw
swelling in the hind limbs using caliper measurements
every 3-4 days. To determine whether 19F MRI could be
used to monitor the effect of drug therapy on established
inflammation, CIA animals were randomized upon disease
onset (day 14) into cohorts of vehicle control or drug treat-
ment for monitoring by serial imaging. Therapy consisted
of daily prednisolone (Sigma Chemical Company, St. Louis,
MO; 10 mg/kg, selected as a model therapeutic due to its
efficacy in treating existing disease) or vehicle control (1%
hydroxyethylcellulose, 0.25% tween-80, 0.05% antifoam),
dosed daily by oral gavage (3.4 ml/kg). The PFC contrast
agent was administered prior to each imaging session to
evaluate the active inflammatory response at the time of
imaging. A schema of the study design is shown in
Figure 1.
Magnetic Resonance Imaging
For in vivo imaging studies V-Sense, a sterile PFC-
containing emulsion (20% (v/v) of perfluoropolyether,
VS-1000H, Celsense, Inc., Pittsburgh, PA) was used as a
Figure 1 Study schema for serial monitoring of arthritic
inflammation & disease. Six rats were injected intradermally with
Type II collagen (CII) in incomplete Freund’s adjuvant on days 0 and
7. Animals were randomized into study cohorts (3 per group) on
day 13, and all injected with PFC contrast agent. Two days later
animals were imaged by 1H 19F MRI, and placed on daily vehicle or
prednisolone for the duration of the study. MRI was repeated at
weekly intervals 48 hours after contrast agent administration. Clinical
measurements of ankle swelling and animal weight were conducted
from day 15 (after the initial collagen immunization) to study end,
every 3 to 4 days.
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Forty-eight hours prior to imaging, a single 1.5 mL dose
was administered intravenously through the tail vein.
MRI was conducted using a Varian 7T DirectDrive MRI
spectrometer (Agilent Technologies, Santa Clara, CA)
equipped with VnmrJ 2.2 C acquisition software, RHEL 4.
u.3 OS, the Magnex 205/120/HD gradient set, a 35 mm i.
d. transmit/receive volume coil, tunable for 1H or 19F im-
aging (m2m Imaging Corp., Cleveland, OH) and a physio-
logical monitoring system (Small Animal Instruments, Inc.
Stony Brook, NY). Rats were anesthetized with 5% isoflurane
and maintained with an anesthesia nose cone at 1.5% isoflur-
ane in oxygen. Prone rats were positioned with hind limbs
extended and an external reference tube (containing 1:15
dilution of the PFC contrast agent in 1% agarose gel, and a
known number of 19F atoms (i.e., spins/mm3) to enable
quantitative measurement of fluorine content) placed be-
tween the legs, affixed to the animal cradle, and guided into
the RF coil. Respiration and body temperature were moni-
tored throughout image acquisition, and bore temperature
was maintained below 30C.
The 1H image was obtained with a fast spin-echo se-
quence, multislice (21 slices, 1 mm thick), and high-
resolution axial images along the length of the hind limbs,
rostral and caudal to the ankles. The acquisition parameters
were: repetition time/echo time (TR/TE)=2000/22 ms,
using a rapid acquisition with refocused echo (RARE) se-
quence, RARE factor=8, 256×256 matrix, field of view
(FOV)=40 x 40 mm2, 2 averages, total acquisition time 2.1
minutes. For 19F images, a RARE sequence was used with
TR/TE=1800/10.1 ms, RARE factor=8, 128×64 matrix
zerofilled to 256 x 256, FOV 40 x 40 mm2, 128 averages, 21
slices and a total acquisition time of 30.7 minutes. The
Larmor frequencies of 1H and 19F differ by ~6%.19F MRI data analysis
Each MR imaging session included a reference tube con-
taining a known dilution of the PFC contrast agent pre-
pared at a concentration of 2.76 x 1017 spins/mm3. Voxel
Tracker™ software (Celsense, Inc.) was used to correct for
the effects of the Rician noise distribution inherent in MRI
and to compare signal intensity from a region of interest to
that of the reference tube to allow determination of the
total amount of fluorine [38-40]. Regions of interest (ROIs)
were drawn in the (1) noise region (2) reference material
regions (3) right/left leg in each image slice. In most
instances, no signal was observed in the first or last slice,
indicating that the majority of the signal was within the
area of analysis.
Histology
On day 29, after the final scan, animals were anesthetized by
CO2 inhalation and euthanized by cervical dislocation, and
ankles and knees fixed in 10% neutral buffered formalin,
then decalcified prior to embedding in paraffin. Sections
were stained with hematoxylin/eosin to assess inflamma-
tion/cellular infiltration within the joints. Images were cap-
tured with an Olympus Provis light microscope, and
sections were also digitized with a microscope slide scanner.
Statistical analysis
Dunnetts’ method was used for comparisons of multiple
cohorts. Two factor ANOVA was used to evaluate signifi-
cance of longitudinal and treatment differences, followed
by ad-hoc comparison of means using Tukey’s method.
Paired T-tests were used to evaluate differences in the
same animal at different time points, and unpaired T-tests
were used to evaluate differences between cohorts. Error
bars represent standard deviation.
Results
To determine whether 19F MRI could be used to image in-
flammation in arthritis, a cohort of rats were immunized
twice with type II collagen to induce disease, and then
dosed with the PFC contrast agent two days prior to 19F
MRI. The time point for imaging (day 15) was selected as
it coincided with nearly complete disease onset (90%) as
measured by ankle swelling. Following MRI acquisition,
19F images were rendered in hot-orange pseudocolor and
overlayed on the anatomical 1H image using Voxel
Tracker™ software. A representative overlay is shown in
Figure 2A. While all CIA rats had a strong 19F signal sur-
rounding the bones in the ankles on day 15, consistent
with the presence of inflammation at those sites, naïve rats
did not have any detectable 19F in the hind limbs
(Figure 2B), consistent with an absence of inflammation.
Figure 2C depicts the entire panel of overlayed 1 mm axial
slices through the hind limbs obtained from a single repre-
sentative diseased rat.
Figure 2 Representative 1H and 19F MRI overlays of rat ankles. A. 19F signal is rendered in hot orange scale and overlayed on a grayscale
1H image in this representative slice from an arthritic rat. B. Representative slice from a naïve rat indicating the placement of right ankle (RA) left
ankle (LA), tail and reference tube (Ref). C. Complete series of 19F slices obtained through the ankles of a representative arthritic rat on day 15.
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interest with the known concentration of fluorine in the
reference enabled the calculation of 19F nuclei per slice
(Figure 3A) to identify the major sites of inflammatory
infiltrates which have taken up 19F along the axis of the
ankle. A 3D reconstruction of the distribution of 19F signal
is depicted in Figure 3B.
In order to correlate 19F signal with the clinical measure-
ment, caliper measurements were obtained from diseased
animals at the time of imaging. Animals imaged prior to
disease onset on day 10 exhibited no swelling in the hind
limbs and also had no detectable 19F signal (n=3, data not
shown). In animals with clinically evident disease imaged
on day 15, four of six animals exhibited a strong linear de-
pendence between diameter and 19F intensity (R2= 0.93),
while two of the six animals exhibited swelling with a
lower, but still detectable, content of 19F. In these two ani-
mals, a very strong 19F signal was observed in the tail nearthe injection site (Figure 4B), in contrast with the other
four animals, where little 19F was detectable in the tail. A
strong correlation (R=0.96) was observed between the
caliper measurement of the ankle and the total amount of
19F signal (Figure 4A) when the animals with high signal in
the tail were excluded from analysis.
To determine whether 19F MRI could be used to evaluate
the course of disease (progression, or remission), cohorts
of animals were serially imaged at weekly intervals follow-
ing the onset of disease. At day 15, all animals had 19F sig-
nal in one or both of their ankles, as shown in Figures 5A
(average signal of all ankles 4.87 x 1019± 4.50 x 1019 range:
1.66 x 1018 to 1.12 x 1020). Evaluation of the 19F signal over
time indicated a significant difference among groups
(Additional file 1: Table S1, P=3.47 x 10-4). Upon treat-
ment with the steroid prednisolone, no significant increase
in 19F signal was detected in the hind limbs at day 22 and
only a minor increase over day 15 was observed by day 29,
Figure 3 Quantification and 3D rendering of inflammation obtained from 19F signal in rat ankles. A. ROIs were drawn around each ankle
and the tail in an image stack from a representative scan of an arthritic rat (day 15) to enable the calculation of 19F spins per slice. The reference
tube containing a known concentration of 19F was used in calculations. Results are represented as the amount of 19F per slice in each of the
ankles or tail, with images depicted for slices 7, 9 and 17. B. 3D rendering of spatial accumulation of 19F signal in the ankles of a representative
arthritic animal (day 15). 1H image is depicted on the left, and fused 19F/1H image in the middle, and 19F on the right.
Figure 4 Correlation between clinical measure of disease and
19F MRI imaging. A. Clinical measurements of disease severity
manifested as ankle swelling were obtained through caliper
measurements of ankle thickness and were plotted versus the total 19F
spins/ankle as measured from the MRI images on day 15 (◆). Solid line
represents the linear trend generated from data on individual ankles
(n= 12). Two animals had very high levels of 19F found in the tail near
the site of tail vein injection, suggesting that V-Sense was not delivered
into the circulation. These two animals (⋄) had significantly lower
levels of 19F in each ankle than animals with similar clinical
measurements (p< 0.001), and were not included in the linear
regression. B. Representative slices from animals without (◆) and with
(⋄) high 19F in the tail are shown.
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additional recruitment of inflammatory cells at later time
points (Figure 5B, Additional file 1: Table S1). In strong
contrast there were highly significant increases in 19F signal
detected in the vehicle control cohort, consistent with pro-
gressive disease and the persisting recruitment of inflamma-
tory phagocytic cells (Figure 5B, Additional file 1: Table S1).
While the 19F intensity was variable among individual ani-
mals (Figure 5B), serial evaluation of the change in signal
revealed that animals with untreated progressive disease
accumulated significantly more 19F signal as compared to
the prednisolone group (Figure 5C; P=7.29 x 10-6 at day
22; P=1.65x10-8 at day 29). Clinical evaluation of hind limb
swelling corroborated the imaging observations of the ef-
fectiveness of prednisolone for reducing swelling versus the
control group (Figure 6A, B). To validate the efficacy of
treatment, animals were sacrificed on day 29, and ankles
and knees were fixed and paraffin-embedded for histo-
logical assessments. As shown in Figure 7, vehicle control
treated CIA animals had large inflammatory infiltrates in
both ankles and knees, while treated animals had markedly
reduced synovitis, consistent with the resolution of the in-
flammatory process in the treated groups as measured by
both 19F MRI and clinical measurements.
Discussion
19F MRI with a PFC contrast agent is emerging as an effect-
ive approach to evaluate the onset of inflammation in both
acute and chronic diseases [28-34]. Our results extend
these findings to the detection and evaluation of CIA, amodel with a quantifiable clinical surrogate of disease se-
verity, enabling a direct comparison of disease activity with
the 19F signal. Numerous studies have co-located the per-
fluorocarbon reagent within macrophage at the site of
Figure 5 Serial imaging and quantification of inflammation and therapeutic response in arthritic rats. As depicted in Figure 4, arthritic
rats undergoing steroid treatment or vehicle control underwent serial imaging with PFC contrast agent and 19F MRI. A. Representative slices from
each of three control animals (1, 2, 3) and each of three treated animals (4, 5, 6) are depicted on days 15, 22 and 29. Each column represents
slices from a single, serially imaged animal over time. B. The degree of inflammation as assessed by quantification of the concentration of 19F per
limb was depicted over time in vehicle (left) and prednisolone treated (right) animals. C. The average change in 19F signal from ti (day 15, the
initial imaging session) to tn (day 22 or day 29) in untreated (open columns) and prednisolone treated (filled columns) at days 22 and day 29 are
shown. *Statistically significant as determined by unpaired T-test (P =7.29 x10-6 at day 22 and P =1.65 x10-8 at day 29).
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teristic of inflammation at the cell-function level [33,37].
The detection of the 19F signal in diseased animals in this
and other studies [28-34] and the lack of 19F signal in naïve
animals indicates the specificity of this imaging approach.
However, it was not clear whether the intensity of the signal
could be used as an independent measure of disease activ-
ity. This study is the first to extend previous findings of the
presence of inflammation to show the potential of 19F MRI
to reveal the severity of inflammation. More importantly,
serial 19F MRI monitoring could effectively be used to
evaluate the persistence of inflammatory responses, pro-
gression of disease, and longitudinal study of the response
to therapy. Limitations of the present study include the lack
of methods to detect PFC within individual phagocytes at
the site of inflammation histologically, and the relative in-
sensitivity of MRI to detect very low amounts of 19F which
might be present at sites of minimal but potentially relevant
inflammation, leading to a false negative. We have recently
developed a dual mode fluorescent version of the PFC con-
trast agent which will facilitate the evaluation of specific
cells containing the contrast agent in future studies. Thedata reported here indicate the utility of PFC contrast agent
with 19F MRI for monitoring the course of disease to assess
the efficacy of a therapeutic.
Early in the disease process, a marked difference be-
tween individual animals was found, both in disease se-
verity as well as in the accumulation of contrast agent. A
linear relationship was observed between the amount of
contrast agent at the site of inflammation and a clinical
measurement of the severity of the experimental disease.
In two subjects a high accumulation of contrast agent
appeared in the tail (Figure 3B), with a lower level of 19F
signal relative to ankle swelling measurement. Arthritis
in the CIA model is typically restricted to the fore and
hind limbs without axial involvement [35], and no clin-
ical signs of disease were noted in the tails of any sub-
jects. We surmised that signal in the tail could be a
consequence of failure to completely deliver the contrast
agent into the bloodstream, and the resulting misadmi-
nistration enabled the local accumulation of the PFC
emulsion at the site of injection, effectively reducing the
amount systemically available to label circulating phago-
cytes. These results indicate that while the intensity of
Figure 6 Clinical measurements of ankle size. A. Ankle swelling in 3 cohorts, naïve (Δ), diseased treated (□) and diseased vehicle control (◇)
are plotted over time. B. Change in ankles size expressed as area under the curve (AUC). * P< 0.0001 as compared to vehicle control using
Dunnett’s method.
Figure 7 Representative hematoxylin- and eosin-stained histologic sections of rat knees and ankles on day 29. Each cohort was
evaluated and examples are depicted of naïve controls (A, D, and G), vehicle-control treated CIA rats (B, E, and H) and prednisolone-treated
CIA rats (C, F, and J). Images include photomicrographs of ankles (A, B, and C; 20X objective) and knees (D, E, and F; 10X objective) and knees
taken with a slide scanner (G, H, and J). Inflammatory cell infiltration (arrows) is found in vehicle-control treated CIA rats.
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ease severity, care in administration of the contrast agent
is necessary for the most reliable readout.
In the serial imaging studies, a difference in the pat-
tern of 19F accumulation over time was found between
the vehicle control and prednisolone treated cohorts. In
the control cohort, 19F signal in the diseased limbs con-
tinued to accumulate upon repeated administration,
whereas in the treated cohort, the signal remained stable
over time, even after repeat administration of contrast
agent. Histological and caliper measurements of ankle
swelling point to continued infiltration of macrophage in
the vehicle control cohort, consistent with 19F measure-
ments. Histological endpoints and caliper measurements
show fewer inflammatory cells and less swelling in the
treated group, and a stable 19F signal. While 19F MRI did
accurately reflect the abatement of macrophage infiltra-
tion to the site of inflammation (i.e., no increases in 19F
were observed in treated animals), the persistence of sig-
nal after the departure of disease points to the need for
future study and characterization of tissue clearance
mechanisms and timescales of the 19F reagent. While a
simple linear correlation between ankle swelling and 19F
signals was not observed in the context of repeated ad-
ministration of the contrast agent at days 22 and day 29
(data not shown), the 19F results nonetheless reflected
the clinical responses, in which increases in 19F reflected
disease progression and the inhibition of further 19F ac-
cumulation in animals undergoing successful therapy
with a measureable clinical response. This data points to
the utility of 19F imaging as a surrogate biomarker for
evaluating therapeutic efficacy in RA.
While the CIA model in rats is largely restricted to the
fore and hind limbs, and can be clinically assessed by
measuring changes in ankle size, not all inflammatory
diseases provide for a facile, rapid measurement of a re-
sponse to a therapeutic drug [41]. Arthritis which affects
the axial skeleton, such as ankylosing spondylitis or
spondyloarthropathy, does not present simple external
measurements for disease severity in preclinical models
[42] and MRI is a standard clinical practice in the diag-
nosis of the disease [43]. In this case, the 19F MRI
method of precisely measuring site-specific inflamma-
tion in vivo could enable an opportunity to facilitate
study and treatment of disease, aiding the clinical devel-
opment of therapeutics for ankylosing spondylitis and
other inflammatory conditions [29,33,34].
As a preclinical tool, 19F MRI may have advantages
over histological evaluation of tissues, given that a single,
live animal may be imaged in less than one hour. In con-
trast, histology requires biopsy or necropsy of the par-
ticular tissues of interest, followed by fixation,
preparation of frozen tissue blocks or paraffin embed-
ding, slicing and mounting tissue sections, then stainingand cover-slipping slides before the tissue is evaluated
microscopically. 19F is taken up by macrophages in situ,
and the signal intensity at sites of inflammation is dir-
ectly related to the degree of cellular macrophage infil-
tration [29,31,33,34], providing a rapid means of
assessing inflammatory infiltration. Further, MR meth-
ods provide more comprehensive information of the ex-
tent and location of inflammation compared with
selected representative tissue sections evaluated by hist-
ology for phagocytic cells, although it may not replace
detailed evaluation of cell subsets or subcellular biomar-
kers. MRI also allows longitudinal studies in the same
animal over time, without biopsy or other invasive pro-
cedures, such as synovial aspiration [44]. Ultimately, this
may speed the screening of inflammatory drugs against
disease, particularly for those diseases where an external
measurement on a live animal is unavailable. In the ab-
sence of imaging equipment, excised tissues may also be
evaluated by 19F NMR spectrometers [28] for a more
high throughput approach to quantitatively evaluate in-
flammatory lesions, with tissue potentially amenable to
histology following NMR analysis.
While the goal of this study was to evaluate the imaging
potential, there were several incidental findings. The detec-
tion of high amounts of 19F in the proximity of the injec-
tion site suggests that tail vein injection was less successful
then one might have predicted, and that inclusion of the
contrast agent could enable one to quantify misadministra-
tion. It was also noted that administration of multiple large
doses of the PFC contrast agent occurred in the absence of
anaphylaxis or adverse clinical effects. While more exten-
sive preclinical toxicological safety testing are necessary
prior to drawing conclusions, the results here contribute to
the accumulating data regarding the safety of systemic PFC
administration for imaging and other applications [45-47].
Conclusions
Pairing a PFC contrast agent with 19F MRI in vivo
enabled a highly specific indicator of disease activity that
has a direct correlation with a clinical measurement (i.e.,
ankle swelling in the CIA model). Here, it is shown that
19F MRI with a PFC contrast agent is not only useful for
identification of sites of inflammation in RA, but can
serve as a quantitative indicator of disease activity, in-
cluding detection of disease progression, or remission in
response to a therapeutic when applied to longitudinal
in vivo imaging studies. The ability to unambiguously
discern the infiltrating inflammatory cells from other
anatomical features is highly desirable for the ability to
quantify and sensitively detect disease progression. As
the 19F signal does not alter the ability to acquire typical
anatomical 1H images, imaging of both inflammation
and the unadulterated anatomical features are possible
with this approach. This approach may facilitate the drug
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therapeutic regimens for RA and other inflammatory-
based diseases, and eventually enable image-guided inter-
ventions or inform the therapeutic decision process in
the clinic.
Additional file
Additional file 1: Table S1. Longitudinal analysis of 19F signal in CIA rats.
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